---
title: "Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: References"
description: "Reference list for the formulary evidence report on Anaphylm (dibutepinephrine, AQST-109) in Type I allergic reactions including anaphylaxis. 122 cited documents."
canonical: "https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/references"
published: "2026-09-21T21:39:21-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: References

<a id="references"></a>

## 5 References

1. [Acaster et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7517656/)
2. [Adamis Pharmaceuticals (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207534s012lbl.pdf)
3. [Alsaggaf et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6886273/)
4. [Aquestive Therapeutics AAAAI poster presentations (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-present-positive-data-pharmacokinetic-and)
5. [Aquestive Therapeutics complete response letter announcement (2026)](https://www.globenewswire.com/news-release/2026/02/02/3230115/0/en/aquestive-therapeutics-announces-fda-issuance-of-complete-response-letter-for-anaphylm.html)
6. [Aquestive Therapeutics corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000007/corporatepresentationfeb.htm)
7. [Aquestive Therapeutics EPIPHAST II results (2022)](https://www.globenewswire.com/news-release/2022/09/27/2523150/0/en/Aquestive-Therapeutics-Announces-Positive-EPIPHAST-II-Trial-Data-for-AQST-109-When-Compared-to-EpiPen.html)
8. [Aquestive Therapeutics EPIPHAST Part 1 results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001397/exh_991.htm)
9. [Aquestive Therapeutics EPIPHAST Part 2 results (2022)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-part-2)
10. [Aquestive Therapeutics EPIPHAST Part 3 final results (2022)](https://www.globenewswire.com/en/news-release/2022/07/11/2477213/0/en/Aquestive-Therapeutics-Reports-Positive-Results-from-Final-Two-Arms-of-EPIPHAST-Trial-Supporting-Performance-and-Real-World-Functionality-of-AQST-109-Epinephrine-Oral-Film.html)
11. [Aquestive Therapeutics EPIPHAST Part 3 initial results (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000162828022017268/aqstepiphastpart3-arm1xt.htm)
12. [Aquestive Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm)
13. [Aquestive Therapeutics human factors and pharmacokinetic study announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-human-factors)
14. [Aquestive Therapeutics investor day presentation (2021)](https://www.sec.gov/Archives/edgar/data/1398733/000114036121009914/brhc10022248_ex99-1.htm)
15. [Aquestive Therapeutics investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000044/hcwpresentation9-11x2026.htm)
16. [Aquestive Therapeutics NDA acceptance announcement (2025)](https://www.globenewswire.com/news-release/2025/06/16/3099704/0/en/Aquestive-Therapeutics-Announces-FDA-Acceptance-of-New-Drug-Application-and-PDUFA-Date-for-Anaphylm-for-the-Treatment-of-Severe-Allergic-Reactions.html)
17. [Aquestive Therapeutics NDA resubmission acceptance announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-fda-acceptance-anaphylmtm-nda)
18. [Aquestive Therapeutics NDA resubmission announcement (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-resubmission-new-drug)
19. [Aquestive Therapeutics oral allergy syndrome study presentation (2024)](https://www.sec.gov/Archives/edgar/data/1398733/000162828024043505/oassupplementarymaterial.htm)
20. [Aquestive Therapeutics oral allergy syndrome study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-results-oral)
21. [Aquestive Therapeutics patent US 12,427,121 (2025)](https://patents.google.com/patent/US12427121B2/en)
22. [Aquestive Therapeutics pediatric study results (2025)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-positive-topline-pk-results-its)
23. [Aquestive Therapeutics phase 1 topline results (2021)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-phase-1)
24. [Aquestive Therapeutics phase 3 first participant dosed (2023)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-doses-first-patient-phase-3-pivotal)
25. [Aquestive Therapeutics phase 3 topline results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-pivotal-study-anaphylmtm)
26. [Aquestive Therapeutics pre-IND response (2021)](https://www.globenewswire.com/news-release/2021/12/13/2350753/0/en/Aquestive-Therapeutics-Receives-Written-Response-to-Pre-IND-Submission-for-AQST-109-epinephrine-prodrug-sublingual-film-and-Begins-Recruitment-for-its-Epinephrine-Film-Pharmacokine.html)
27. [Aquestive Therapeutics second quarter 2026 earnings presentation (2026)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000041/q22026supplementalearnin.htm)
28. [Aquestive Therapeutics second quarter 2026 results (2026)](https://www.globenewswire.com/news-release/2026/08/11/3343140/0/en/aquestive-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html)
29. [Aquestive Therapeutics self-administration study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-anaphylmtm)
30. [Aquestive Therapeutics temperature and pH study results (2024)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-reports-positive-topline-data-temperature)
31. [Aquestive Therapeutics Type A meeting completion (2026)](https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-announces-completion-type-meeting-fda)
32. [Armstrong et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4780888/)
33. [Arroyo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8277683/)
34. [ARS Pharmaceuticals (2024)](https://ir.ars-pharma.com/news-releases/news-release-details/ars-pharmaceuticals-receives-fda-approval-neffyr-epinephrine)
35. [ARS Pharmaceuticals (2025)](https://downloads.regulations.gov/FDA-2025-P-4105-0001/attachment_1.pdf)
36. [ARS Pharmaceuticals (2026)](https://www.ars-pharma.com/wp-content/uploads/pdf/Prescribing_Information.pdf)
37. [ARS Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097478/spry-20251231.htm)
38. [ASHP (2026)](https://www.drugs.com/monograph/epinephrine.html)
39. [Baseggio Conrado et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7885259/)
40. [Bekis Bozkurt and Pençe (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12613457/)
41. [Bilaver et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27244806/)
42. [Bilaver et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30703439/)
43. [Blumenthal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5862726/)
44. [Brettig et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40249561/)
45. [Bunke et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40310682/)
46. [Cardona et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7607509/)
47. [Centers for Medicare and Medicaid Services NADAC (2025)](https://data.medicaid.gov/api/1/datastore/query/f38d0706-1239-442c-a3cc-40ef1b686ac0/0?limit=5&conditions%5B0%5D%5Bproperty%5D=ndc&conditions%5B0%5D%5Bvalue%5D=49502050002&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=as_of_date&conditions%5B1%5D%5Bvalue%5D=2025-11-12&conditions%5B1%5D%5Boperator%5D=%3D)
48. [Centers for Medicare and Medicaid Services NADAC (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?limit=20&conditions%5B0%5D%5Bproperty%5D=as_of_date&conditions%5B0%5D%5Bvalue%5D=2026-09-16&conditions%5B0%5D%5Boperator%5D=%3D&conditions%5B1%5D%5Bproperty%5D=ndc&conditions%5B1%5D%5Boperator%5D=in&conditions%5B1%5D%5Bvalue%5D%5B%5D=49502010202&conditions%5B1%5D%5Bvalue%5D%5B%5D=60842002301&conditions%5B1%5D%5Bvalue%5D%5B%5D=82580002002)
49. [Chowdhury et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13108942/)
50. [ClinicalTrials.gov NCT06527937](https://clinicaltrials.gov/study/NCT06527937)
51. [ClinicalTrials.gov NCT07703982](https://clinicaltrials.gov/study/NCT07703982)
52. [Commins (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5381731/)
53. [DailyMed NEFFY label (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1758142-a905-401d-8961-05829f51023a)
54. [Dribin (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13539609/)
55. [Dribin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8604419/)
56. [Dribin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10085823/)
57. [Dribin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12301991/)
58. [Ellorin and Agrawal (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13120779/)
59. [Engel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11921788/)
60. [Fortune Business Insights (2026)](https://www.fortunebusinessinsights.com/u-s-epinephrine-for-anaphylaxis-treatment-market-110494)
61. [Golden et al. (2023)](https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Allergist%20Resources/Statements%20and%20Practice%20Parameters/Anaphylaxis-Practice-Paramaters-2023.pdf)
62. [Golden et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41297629/)
63. [Golding et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35338731/)
64. [Greenhawt and Shaker (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6991237/)
65. [Gupta et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24042236/)
66. [Gupta et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6317772/)
67. [Gupta et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6324316/)
68. [Gurkha et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9938607/)
69. [Herbert et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7825384/)
70. [Hirata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11749445/)
71. [Höfer et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37816460/)
72. [Iglesia et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11060332/)
73. [Jeong and Lee (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10694555/)
74. [Jerschow et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4260987/)
75. [Jiang et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10267771/)
76. [Jimenez-Garcia et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11387914/)
77. [Kraus et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39826899/)
78. [Lee (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7592897/)
79. [Lee et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25680923/)
80. [Lee et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5172382/)
81. [Lieberman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8247890/)
82. [Lieberman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37279803/)
83. [Ma et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3972293/)
84. [McKenzie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12983974/)
85. [McMurray et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11994729/)
86. [Nasser et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42466634/)
87. [Nduwimana et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12335364/)
88. [Newman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8984676/)
89. [Nguyen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8346007/)
90. [Nowak-Wegrzyn et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42365874/)
91. [Oppenheimer et al. (2022)](https://www.sec.gov/Archives/edgar/data/1398733/000117184322001488/exh_992.htm)
92. [Patel et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21489610/)
93. [Pouessel and Neukirch (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11707320/)
94. [Poziomkowska-Gęsicka and Kurek (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7215547/)
95. [Pühringer et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10749935/)
96. [Ray et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10590739/)
97. [Robinson et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8145784/)
98. [Sampson et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16461139/)
99. [Sato et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12402951/)
100. [Shaker and Greenhawt (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6324395/)
101. [Shaker and Greenhawt (2019a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439603/)
102. [Shaker and Greenhawt (2019b)](https://pubmed.ncbi.nlm.nih.gov/31201119/)
103. [Shaker et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28634019/)
104. [Shaker et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33486143/)
105. [Shaker et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39637974/)
106. [Sim et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11707323/)
107. [Sindher et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39087236/)
108. [Smith et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13118655/)
109. [Spergel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13400411/)
110. [Spolidoro et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10099188/)
111. [Turner et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5123619/)
112. [Turner et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5589409/)
113. [Viatris (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/019430s120lbl.pdf)
114. [Volerman et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8884139/)
115. [Warren et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29936229/)
116. [Warren et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7883751/)
117. [Warren et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9190169/)
118. [Warren et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10217773/)
119. [WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index (2026)](https://atcddd.fhi.no/atc_ddd_index/?code=C01CA24)
120. [Worm et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12350582/)
121. [Yin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11755952/)
122. [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12061005/)

## Related pages
- [Anaphylm (dibutepinephrine): Type I allergic reactions including anaphylaxis](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Terms and abbreviations](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/terms-and-abbreviations.md)
- [Anaphylm (dibutepinephrine): Type I allergic reactions including anaphylaxis](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/executive-summary.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Product information and disease description](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/product-information-and-disease-description.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Clinical evidence](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/clinical-evidence.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Economic information and modeling report](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/economics) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/economics.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: prevalence by geography](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/prevalence) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/prevalence.md)
- [Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/cost-effectiveness-analyses.md)
